

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on April 21, 2005.

Amy Yost
Amy Yost
Date of Signature April 21, 2005

Rec'd PCT/PTO 25 APR 2005

10/529071

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Li et al.

Group Art Unit: Not assigned

Serial No.: 10/529,071

Examiner: Not assigned

Filed: March 24, 2005

Docket No.: 180/156 PCT/US

For: TARGETED TUMOR THERAPY BY USE OF RECOMBINANT ADENOVIRUS
VECTORS THAT SELECTIVELY REPLICATE IN HYPOXIC REGIONS OF
TUMORS

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. 1.56, 1.97, and 1.98, applicants' undersigned attorney brings to the attention of the Patent and Trademark Office the documents listed on the attached Form PTO-1449. Copies of the references as well as Form PTO-1449 are attached hereto. This is not to be construed as a representation that a search has been made or that a reference is relevant merely because cited.

Early passage of the subject application to issue is earnestly solicited.

Serial No.: 10/529,071


Although it is believed that no fee is due, the Commissioner is hereby authorized to charge any fees associated with the filing of this Information Disclosure Statement to Deposit Account No. 50-0426.

Respectfully submitted,

JENKINS, WILSON & TAYLOR, P.A.

Date: 04/21/2005

By:


Arles A. Taylor, Jr.
Registration No. 39,395

AAT/acy

Enclosures

Customer No: 25297

FORM PTO-1449 U.S. Department of Commerce
Patent and Trademark Office

List of Documents Cited by Applicant



Application No.:	10/529,071
Filing Date:	March 24, 2005
First Named Inventor:	Li et al.
Group:	Not assigned
Examiner:	Not assigned
Attorney Docket No.:	180/156 PCT/US

U.S. PATENT DOCUMENTS


Examiner Initial	Cite No.	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, where relevant passages or relevant figures appear
	1	US 2001/0053352	12/20/2001	Yu et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Document Number (country code, no., kind code (if known))	Publication Date	Name of Patentee or Applicant	Pages, columns, lines where relevant passages appear	T
	2	WO 98/35028	8/13/1998	Aleman et al.		
	3	WO 02/26192	4/42002	Van Meir et al.		

OTHER DOCUMENTS

Examiner Initials	Cite No.	Include Author (in CAPITAL LETTERS), Title, Journal, Date, Pertinent Pages, Etc.	T
	4	International Search Report corresponding to PCT App. No. PCT/US03/31097 dated April 21, 2004.	
	5	HUANG ET AL., "A Hypoxia-Selective Oncolytic Adenovirus for Cancer Therapy", <u>I. J. Radiation Oncology</u> , 54(2) Supplement : 122, 2002.	
	6	LIU ET AL., "Hypoxia regulates vascular endothelial growth factor gene expression in endothelial cells", <u>Circulation Research</u> , 77(3) : 638, September 1995.	
	7	SHIBATA ET AL., "Enhancement of gene expression under hypoxic conditions using fragments of the human vascular endothelial growth factor and the erythropoietin genes", <u>I.J. Radiation Oncology Biol. Phys.</u> , 42(4) : 913-916, 1998.	



8	BOSHART ET AL., "A very strong enhancer is located upstream of an immediate early gene of human cytomegalovirus", <u>Cell</u> , 41 : 521-530, June 1995.	
9	HERNANDEZ-ALCOCEBA ET AL., "New oncolytic adenoviruses with hypoxia- and estrogen receptor-regulated replication", <u>Human Gene Therapy</u> , 13 : 1737-1750, September 20, 2002.	
10	POST ET AL., "A novel hypoxia-inducible factor (HIF) activated oncolytic adenovirus for cancer therapy", <u>Oncogene</u> , 22 : 2065-2072, 2003.	
11	SHIBATA ET AL., "Development of a hypoxia-responsive vector for tumor-specific gene therapy", <u>Gene Therapy</u> , 7 : 493-498, 2000.	

EXAMINER _____ DATE CONSIDERED _____

*Examiner Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.